MedTrace Logo

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

NCT03590444 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-07-18

No results posted yet for this study

Summary

Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.

Conditions

  • Diabetic Retinal Edema

Interventions

DRUG

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution

Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution. Ranibizumab 0.5 MG/0.05 ML Intraocular Solution

Sponsors & Collaborators

  • Hospital Hietzing

    lead OTHER

Principal Investigators

  • Christopher Schütze, Ass.Prof. MD · Hietzing Hospital Vienna, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-02
Primary Completion
2018-04-02
Completion
2018-06-02

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03590444 on ClinicalTrials.gov